<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240603222604&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240603222604&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 04 Jun 2024 02:26:04 +0000</lastbuilddate>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Seeing is Believing: Muscleblind-like 1 Is Necessary For Mammalian Cardiomyocyte Maturation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38829935/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 4;149(23):1830-1832. doi: 10.1161/CIRCULATIONAHA.124.068657. Epub 2024 Jun 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38829935/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38829935</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068657>10.1161/CIRCULATIONAHA.124.068657</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38829935</guid>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Khalid B Dar</dc:creator>
<dc:creator>Shah R Ali</dc:creator>
<dc:date>2024-06-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Seeing is Believing: Muscleblind-like 1 Is Necessary For Mammalian Cardiomyocyte Maturation</dc:title>
<dc:identifier>pmid:38829935</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068657</dc:identifier>
</item>
<item>
<title>Implanted Human Cardiac Spheroids Electrically Couple With Infarcted Swine Myocardium</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38829934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 4;149(23):1855-1857. doi: 10.1161/CIRCULATIONAHA.123.068568. Epub 2024 Jun 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38829934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38829934</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068568>10.1161/CIRCULATIONAHA.123.068568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38829934</guid>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Bijay Guragain</dc:creator>
<dc:creator>Yuhua Wei</dc:creator>
<dc:creator>Hanyu Zhang</dc:creator>
<dc:creator>Asher Kahn-Krell</dc:creator>
<dc:creator>Lei Ye</dc:creator>
<dc:creator>Gregory P Walcott</dc:creator>
<dc:creator>Jack M Rogers</dc:creator>
<dc:creator>Jianyi Jay Zhang</dc:creator>
<dc:date>2024-06-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Implanted Human Cardiac Spheroids Electrically Couple With Infarcted Swine Myocardium</dc:title>
<dc:identifier>pmid:38829934</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068568</dc:identifier>
</item>
<item>
<title>The Future of Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38829933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 4;149(23):1783-1785. doi: 10.1161/CIRCULATIONAHA.123.066982. Epub 2024 Jun 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38829933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38829933</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066982>10.1161/CIRCULATIONAHA.123.066982</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38829933</guid>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:date>2024-06-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Future of Clinical Trials</dc:title>
<dc:identifier>pmid:38829933</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066982</dc:identifier>
</item>
<item>
<title>A Wide Complex Tachycardia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38829932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 4;149(23):1852-1854. doi: 10.1161/CIRCULATIONAHA.124.069785. Epub 2024 Jun 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38829932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38829932</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069785>10.1161/CIRCULATIONAHA.124.069785</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38829932</guid>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Chan-Hee Lee</dc:creator>
<dc:creator>Emily Higgs</dc:creator>
<dc:creator>Melvin M Scheinman</dc:creator>
<dc:date>2024-06-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Wide Complex Tachycardia</dc:title>
<dc:identifier>pmid:38829932</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069785</dc:identifier>
</item>
<item>
<title>Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38829931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 4;149(23):1786-1788. doi: 10.1161/CIRCULATIONAHA.123.066916. Epub 2024 Jun 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38829931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38829931</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066916>10.1161/CIRCULATIONAHA.123.066916</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38829931</guid>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Kathryn A McGurk</dc:creator>
<dc:creator>Nagme Bilgehan</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:date>2024-06-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38829931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066916</dc:identifier>
</item>
<item>
<title>Genetic Architecture and Clinical Outcomes of Combined Lipid Disturbances</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38828614/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Simultaneous assessment of multiple lipid derangements revealed nuanced differences in coronary artery disease risk and genetic architectures across dyslipoproteinemia subtypes. These findings highlight the importance of looking beyond single lipid traits to better understand combined lipid and lipoprotein phenotypes and implications for disease risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 3. doi: 10.1161/CIRCRESAHA.123.323973. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Dyslipoproteinemia often involves simultaneous derangements of multiple lipid traits. We aimed to evaluate the phenotypic and genetic characteristics of combined lipid disturbances in a general population-based cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among UK Biobank participants without prevalent coronary artery disease, we used blood lipid and apolipoprotein B concentrations to ascribe individuals into 1 of 6 reproducible and mutually exclusive dyslipoproteinemia subtypes. Incident coronary artery disease risk was estimated for each subtype using Cox proportional hazards models. Phenome-wide analyses and genome-wide association studies were performed for each subtype, followed by in silico causal gene prioritization and heritability analyses. Additionally, the prevalence of disruptive variants in causal genes for Mendelian lipid disorders was assessed using whole-exome sequence data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 450 636 UK Biobank participants: 63 (0.01%) had chylomicronemia; 40 005 (8.9%) had hypercholesterolemia; 94 785 (21.0%) had combined hyperlipidemia; 13 998 (3.1%) had remnant hypercholesterolemia; 110 389 (24.5%) had hypertriglyceridemia; and 49 (0.01%) had mixed hypertriglyceridemia and hypercholesterolemia. Over a median (interquartile range) follow-up of 11.1 (10.4-11.8) years, incident coronary artery disease risk varied across subtypes, with combined hyperlipidemia exhibiting the largest hazard (hazard ratio, 1.92 [95% CI, 1.84-2.01]; <i>P</i>=2×10<sup>-16</sup>), even when accounting for non-HDL-C (hazard ratio, 1.45 [95% CI, 1.30-1.60]; <i>P</i>=2.6×10<sup>-12</sup>). Genome-wide association studies revealed 250 loci significantly associated with dyslipoproteinemia subtypes, of which 72 (28.8%) were not detected in prior single lipid trait genome-wide association studies. Mendelian lipid variant carriers were rare (2.0%) among individuals with dyslipoproteinemia, but polygenic heritability was high, ranging from 23% for remnant hypercholesterolemia to 54% for combined hyperlipidemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Simultaneous assessment of multiple lipid derangements revealed nuanced differences in coronary artery disease risk and genetic architectures across dyslipoproteinemia subtypes. These findings highlight the importance of looking beyond single lipid traits to better understand combined lipid and lipoprotein phenotypes and implications for disease risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38828614/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38828614</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323973>10.1161/CIRCRESAHA.123.323973</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38828614</guid>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas Gilliland</dc:creator>
<dc:creator>Jacqueline S Dron</dc:creator>
<dc:creator>Margaret Sunitha Selvaraj</dc:creator>
<dc:creator>Mark Trinder</dc:creator>
<dc:creator>Kaavya Paruchuri</dc:creator>
<dc:creator>Sarah M Urbut</dc:creator>
<dc:creator>Sara Haidermota</dc:creator>
<dc:creator>Rachel Bernardo</dc:creator>
<dc:creator>Md Mesbah Uddin</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:creator>Gina M Peloso</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:date>2024-06-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Genetic Architecture and Clinical Outcomes of Combined Lipid Disturbances</dc:title>
<dc:identifier>pmid:38828614</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323973</dc:identifier>
</item>
<item>
<title>Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38828596/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results suggest that the balance between APOB lipoproteins and the larger HDL subspecies contributes to atherosclerosis progression and incident CVD in the setting of T1D and that larger HDLs exert atheroprotective effects on endothelial cells rather than by promoting macrophage cholesterol efflux.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 3. doi: 10.1161/CIRCRESAHA.123.323100. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Individuals with type 1 diabetes (T1D) generally have normal or even higher HDL (high-density lipoprotein)-cholesterol levels than people without diabetes yet are at increased risk for atherosclerotic cardiovascular disease (CVD). Human HDL is a complex mixture of particles that can vary in cholesterol content by >;2-fold. To investigate if specific HDL subspecies contribute to the increased atherosclerosis associated with T1D, we created mouse models of T1D that exhibit human-like HDL subspecies. We also measured HDL subspecies and their association with incident CVD in a cohort of people with T1D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated LDL receptor-deficient (<i>Ldlr</i><sup><i>-/-</i></sup>) mouse models of T1D expressing human APOA1 (apolipoprotein A1). <i>Ldlr</i><sup><i>-/-</i></sup><i>APOA1</i><sup><i>Tg</i></sup> mice exhibited the main human HDL subspecies. We also generated <i>Ldlr</i><sup><i>-/-</i></sup><i>APOA1</i><sup><i>Tg</i></sup> T1D mice expressing CETP (cholesteryl ester transfer protein), which had lower concentrations of large HDL subspecies versus mice not expressing CETP. HDL particle concentrations and sizes and proteins involved in lipoprotein metabolism were measured by calibrated differential ion mobility analysis and targeted mass spectrometry in the mouse models of T1D and in a cohort of individuals with T1D. Endothelial transcytosis was analyzed by total internal reflection fluorescence microscopy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Diabetic <i>Ldlr</i><sup><i>-/-</i></sup><i>APOA1</i><sup><i>Tg</i></sup> mice were severely hyperglycemic and hyperlipidemic and had markedly elevated plasma APOB levels versus nondiabetic littermates but were protected from the proatherogenic effects of diabetes. Diabetic <i>Ldlr</i><sup><i>-/-</i></sup><i>APOA1</i><sup><i>Tg</i></sup> mice expressing CETP lost the atheroprotective effect and had increased lesion necrotic core areas and APOB accumulation, despite having lower plasma APOB levels. The detrimental effects of low concentrations of larger HDL particles in diabetic mice expressing CETP were not explained by reduced cholesterol efflux. Instead, large HDL was more effective than small HDL in preventing endothelial transcytosis of LDL mediated by scavenger receptor class B type 1. Finally, in humans with T1D, increased concentrations of larger HDLs relative to APOB100 negatively predicted incident CVD independently of HDL-cholesterol levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results suggest that the balance between APOB lipoproteins and the larger HDL subspecies contributes to atherosclerosis progression and incident CVD in the setting of T1D and that larger HDLs exert atheroprotective effects on endothelial cells rather than by promoting macrophage cholesterol efflux.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38828596/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38828596</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323100>10.1161/CIRCRESAHA.123.323100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38828596</guid>
<pubDate>Mon, 03 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vishal Kothari</dc:creator>
<dc:creator>Tse W W Ho</dc:creator>
<dc:creator>Ainara G Cabodevilla</dc:creator>
<dc:creator>Yi He</dc:creator>
<dc:creator>Farah Kramer</dc:creator>
<dc:creator>Masami Shimizu-Albergine</dc:creator>
<dc:creator>Jenny E Kanter</dc:creator>
<dc:creator>Janet Snell-Bergeon</dc:creator>
<dc:creator>Edward A Fisher</dc:creator>
<dc:creator>Baohai Shao</dc:creator>
<dc:creator>Jay W Heinecke</dc:creator>
<dc:creator>Jacob O Wobbrock</dc:creator>
<dc:creator>Warren L Lee</dc:creator>
<dc:creator>Ira J Goldberg</dc:creator>
<dc:creator>Tomas Vaisar</dc:creator>
<dc:creator>Karin E Bornfeldt</dc:creator>
<dc:date>2024-06-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis</dc:title>
<dc:identifier>pmid:38828596</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323100</dc:identifier>
</item>
<item>
<title>De novo and salvage purine synthesis pathways across tissues and tumors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38823389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>Purine nucleotides are vital for RNA and DNA synthesis, signaling, metabolism, and energy homeostasis. To synthesize purines, cells use two principal routes: the de novo and salvage pathways. Traditionally, it is believed that proliferating cells predominantly rely on de novo synthesis, whereas differentiated tissues favor the salvage pathway. Unexpectedly, we find that adenine and inosine are the most effective circulating precursors for supplying purine nucleotides to tissues and tumors, while...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 30:S0092-8674(24)00520-8. doi: 10.1016/j.cell.2024.05.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Purine nucleotides are vital for RNA and DNA synthesis, signaling, metabolism, and energy homeostasis. To synthesize purines, cells use two principal routes: the de novo and salvage pathways. Traditionally, it is believed that proliferating cells predominantly rely on de novo synthesis, whereas differentiated tissues favor the salvage pathway. Unexpectedly, we find that adenine and inosine are the most effective circulating precursors for supplying purine nucleotides to tissues and tumors, while hypoxanthine is rapidly catabolized and poorly salvaged in vivo. Quantitative metabolic analysis demonstrates comparative contribution from de novo synthesis and salvage pathways in maintaining purine nucleotide pools in tumors. Notably, feeding mice nucleotides accelerates tumor growth, while inhibiting purine salvage slows down tumor progression, revealing a crucial role of the salvage pathway in tumor metabolism. These findings provide fundamental insights into how normal tissues and tumors maintain purine nucleotides and highlight the significance of purine salvage in cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38823389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38823389</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.011>10.1016/j.cell.2024.05.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38823389</guid>
<pubDate>Sat, 01 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Diem H Tran</dc:creator>
<dc:creator>Dohun Kim</dc:creator>
<dc:creator>Rushendhiran Kesavan</dc:creator>
<dc:creator>Harrison Brown</dc:creator>
<dc:creator>Trishna Dey</dc:creator>
<dc:creator>Mona Hoseini Soflaee</dc:creator>
<dc:creator>Hieu S Vu</dc:creator>
<dc:creator>Alpaslan Tasdogan</dc:creator>
<dc:creator>Jason Guo</dc:creator>
<dc:creator>Divya Bezwada</dc:creator>
<dc:creator>Houssam Al Saad</dc:creator>
<dc:creator>Feng Cai</dc:creator>
<dc:creator>Ashley Solmonson</dc:creator>
<dc:creator>Halie Rion</dc:creator>
<dc:creator>Rawand Chabatya</dc:creator>
<dc:creator>Salma Merchant</dc:creator>
<dc:creator>Nathan J Manales</dc:creator>
<dc:creator>Vanina T Tcheuyap</dc:creator>
<dc:creator>Megan Mulkey</dc:creator>
<dc:creator>Thomas P Mathews</dc:creator>
<dc:creator>James Brugarolas</dc:creator>
<dc:creator>Sean J Morrison</dc:creator>
<dc:creator>Hao Zhu</dc:creator>
<dc:creator>Ralph J DeBerardinis</dc:creator>
<dc:creator>Gerta Hoxhaj</dc:creator>
<dc:date>2024-06-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>De novo and salvage purine synthesis pathways across tissues and tumors</dc:title>
<dc:identifier>pmid:38823389</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.011</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: sodium/glucose cotransporter 2 inhibition after myocardial infarction still in the grey area</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38822728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 1:ehae304. doi: 10.1093/eurheartj/ehae304. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38822728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38822728</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae304>10.1093/eurheartj/ehae304</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38822728</guid>
<pubDate>Sat, 01 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-06-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: sodium/glucose cotransporter 2 inhibition after myocardial infarction still in the grey area</dc:title>
<dc:identifier>pmid:38822728</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae304</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: transcatheter aortic valve implantation in patients with small aortic annulus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38822725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 1:ehae308. doi: 10.1093/eurheartj/ehae308. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38822725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38822725</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae308>10.1093/eurheartj/ehae308</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38822725</guid>
<pubDate>Sat, 01 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2024-06-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: transcatheter aortic valve implantation in patients with small aortic annulus</dc:title>
<dc:identifier>pmid:38822725</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae308</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: a novel RNA-based approach to the treatment of hypertriglyceridaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38822724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 1:ehae351. doi: 10.1093/eurheartj/ehae351. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38822724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38822724</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae351>10.1093/eurheartj/ehae351</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38822724</guid>
<pubDate>Sat, 01 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-06-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: a novel RNA-based approach to the treatment of hypertriglyceridaemia</dc:title>
<dc:identifier>pmid:38822724</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae351</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Impella CP in myocardial infarction complicated by cardiogenic shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38822722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 1:ehae306. doi: 10.1093/eurheartj/ehae306. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38822722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38822722</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae306>10.1093/eurheartj/ehae306</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38822722</guid>
<pubDate>Sat, 01 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2024-06-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Impella CP in myocardial infarction complicated by cardiogenic shock</dc:title>
<dc:identifier>pmid:38822722</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae306</dc:identifier>
</item>
<item>
<title>Optimizing the treatment of severe aortic stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38822641/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 1;45(21):1861-1865. doi: 10.1093/eurheartj/ehae320.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38822641/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38822641</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae320>10.1093/eurheartj/ehae320</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38822641</guid>
<pubDate>Sat, 01 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-06-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Optimizing the treatment of severe aortic stenosis</dc:title>
<dc:identifier>pmid:38822641</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae320</dc:identifier>
</item>
<item>
<title>A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38821050/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>Dolichol is a lipid critical for N-glycosylation as a carrier for activated sugars and nascent oligosaccharides. It is commonly thought to be directly produced from polyprenol by the enzyme SRD5A3. Instead, we found that dolichol synthesis requires a three-step detour involving additional metabolites, where SRD5A3 catalyzes only the second reaction. The first and third steps are performed by DHRSX, whose gene resides on the pseudoautosomal regions of the X and Y chromosomes. Accordingly, we...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 22:S0092-8674(24)00467-7. doi: 10.1016/j.cell.2024.04.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dolichol is a lipid critical for N-glycosylation as a carrier for activated sugars and nascent oligosaccharides. It is commonly thought to be directly produced from polyprenol by the enzyme SRD5A3. Instead, we found that dolichol synthesis requires a three-step detour involving additional metabolites, where SRD5A3 catalyzes only the second reaction. The first and third steps are performed by DHRSX, whose gene resides on the pseudoautosomal regions of the X and Y chromosomes. Accordingly, we report a pseudoautosomal-recessive disease presenting as a congenital disorder of glycosylation in patients with missense variants in DHRSX (DHRSX-CDG). Of note, DHRSX has a unique dual substrate and cofactor specificity, allowing it to act as a NAD<sup>+</sup>-dependent dehydrogenase and as a NADPH-dependent reductase in two non-consecutive steps. Thus, our work reveals unexpected complexity in the terminal steps of dolichol biosynthesis. Furthermore, we provide insights into the mechanism by which dolichol metabolism defects contribute to disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38821050/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38821050</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.041>10.1016/j.cell.2024.04.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38821050</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew P Wilson</dc:creator>
<dc:creator>Takfarinas Kentache</dc:creator>
<dc:creator>Charlotte R Althoff</dc:creator>
<dc:creator>Céline Schulz</dc:creator>
<dc:creator>Geoffroy de Bettignies</dc:creator>
<dc:creator>Gisèle Mateu Cabrera</dc:creator>
<dc:creator>Loreta Cimbalistiene</dc:creator>
<dc:creator>Birute Burnyte</dc:creator>
<dc:creator>Grace Yoon</dc:creator>
<dc:creator>Gregory Costain</dc:creator>
<dc:creator>Sandrine Vuillaumier-Barrot</dc:creator>
<dc:creator>David Cheillan</dc:creator>
<dc:creator>Daisy Rymen</dc:creator>
<dc:creator>Lucie Rychtarova</dc:creator>
<dc:creator>Hana Hansikova</dc:creator>
<dc:creator>Marina Bury</dc:creator>
<dc:creator>Joseph P Dewulf</dc:creator>
<dc:creator>Francesco Caligiore</dc:creator>
<dc:creator>Jaak Jaeken</dc:creator>
<dc:creator>Vincent Cantagrel</dc:creator>
<dc:creator>Emile Van Schaftingen</dc:creator>
<dc:creator>Gert Matthijs</dc:creator>
<dc:creator>François Foulquier</dc:creator>
<dc:creator>Guido T Bommer</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis</dc:title>
<dc:identifier>pmid:38821050</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.041</dc:identifier>
</item>
<item>
<title>Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38820201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae292. doi: 10.1093/eurheartj/ehae292. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Surgical explantation of transcatheter heart valves (THVs) is rapidly increasing, but there are limited data on patients with THV-associated infective endocarditis (IE). This study aims to assess the outcomes of patients undergoing THV explant for IE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All patients who underwent THV explant between 2011 and 2022 from 44 sites in the EXPLANT-TAVR registry were identified. Patients with IE as the reason for THV explant were compared to those with other mechanisms of bioprosthetic valve dysfunction (BVD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 372 patients from the EXPLANT-TAVR registry were included. Among them, 184 (49.5%) patients underwent THV explant due to IE and 188 (50.5%) patients due to BVD. At the index transcatheter aortic valve replacement, patients undergoing THV explant for IE were older (74.3 ± 8.6 vs. 71 ± 10.6 years) and had a lower Society of Thoracic Surgeons risk score [2.6% (1.8-5.0) vs. 3.3% (2.1-5.6), P = .029] compared to patients with BVD. Compared to BVD, IE patients had longer intensive care unit and hospital stays (P &lt; .05) and higher stroke rates at 30 days (8.6% vs. 2.9%, P = .032) and 1 year (16.2% vs. 5.2%, P = .010). Adjusted in-hospital, 30-day, and 1-year mortality was 12.1%, 16.1%, and 33.8%, respectively, for the entire cohort, with no significant differences between groups. Although mortality was numerically higher in IE patients 3 years postsurgery (29.6% for BVD vs. 43.9% for IE), Kaplan-Meier analysis showed no significant differences between groups (P = .16).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38820201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38820201</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae292>10.1093/eurheartj/ehae292</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38820201</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mateo Marin-Cuartas</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Philipp Kiefer</dc:creator>
<dc:creator>Shinichi Fukuhara</dc:creator>
<dc:creator>Rudiger Lange</dc:creator>
<dc:creator>Katherine B Harrington</dc:creator>
<dc:creator>Shekhar Saha</dc:creator>
<dc:creator>Christian Hagl</dc:creator>
<dc:creator>Neal S Kleiman</dc:creator>
<dc:creator>Sachin S Goel</dc:creator>
<dc:creator>Joerg Kempfert</dc:creator>
<dc:creator>Paul Werner</dc:creator>
<dc:creator>George A Petrossian</dc:creator>
<dc:creator>Arnar Geirsson</dc:creator>
<dc:creator>Nimesh D Desai</dc:creator>
<dc:creator>Michael W A Chu</dc:creator>
<dc:creator>Oliver D Bhadra</dc:creator>
<dc:creator>Christian Shults</dc:creator>
<dc:creator>Andrea Garatti</dc:creator>
<dc:creator>Flavien Vincent</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Joshua B Goldberg</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Paolo Denti</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Vinayak N Bapat</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Michael A Borger</dc:creator>
<dc:creator>Syed Zaid</dc:creator>
<dc:creator>EXPLANT-TAVR Investigators</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry</dc:title>
<dc:identifier>pmid:38820201</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae292</dc:identifier>
</item>
<item>
<title>Detect and define ventricular arrhythmia substrates in hypertrophic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38820199/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae312. doi: 10.1093/eurheartj/ehae312. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38820199/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38820199</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae312>10.1093/eurheartj/ehae312</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38820199</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiaxin Wang</dc:creator>
<dc:creator>Xiuyu Chen</dc:creator>
<dc:creator>Shihua Zhao</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Detect and define ventricular arrhythmia substrates in hypertrophic cardiomyopathy</dc:title>
<dc:identifier>pmid:38820199</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae312</dc:identifier>
</item>
<item>
<title>Cannabis use and cardiovascular diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38820197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae313. doi: 10.1093/eurheartj/ehae313. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38820197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38820197</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae313>10.1093/eurheartj/ehae313</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38820197</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Viktor Čulić</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cannabis use and cardiovascular diseases</dc:title>
<dc:identifier>pmid:38820197</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae313</dc:identifier>
</item>
<item>
<title>Programmed ventricular stimulation for risk stratification in hypertrophic cardiomyopathy patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38820196/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae311. doi: 10.1093/eurheartj/ehae311. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38820196/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38820196</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae311>10.1093/eurheartj/ehae311</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38820196</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Petros Arsenos</dc:creator>
<dc:creator>Konstantinos Tsioufis</dc:creator>
<dc:creator>Konstantinos A Gatzoulis</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Programmed ventricular stimulation for risk stratification in hypertrophic cardiomyopathy patients</dc:title>
<dc:identifier>pmid:38820196</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae311</dc:identifier>
</item>
<item>
<title>Unmeasured confounding is always unnerving: cannabis and cardiovascular risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38820180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae314. doi: 10.1093/eurheartj/ehae314. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38820180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38820180</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae314>10.1093/eurheartj/ehae314</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38820180</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Anders Holt</dc:creator>
<dc:creator>Patricia McGettigan</dc:creator>
<dc:creator>Morten Lamberts</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Unmeasured confounding is always unnerving: cannabis and cardiovascular risk</dc:title>
<dc:identifier>pmid:38820180</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae314</dc:identifier>
</item>
<item>
<title>Multiple arterial vs. single arterial coronary artery bypass grafting: sex-related differences in outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38820177/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compared to single arterial grafting, multiple arterial revascularization is associated with improved long-term survival for women as well as men.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae294. doi: 10.1093/eurheartj/ehae294. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Uncertainty exists over whether multiple arterial grafting has a sex-related association with survival after coronary artery bypass grafting. This study aims to compare the long-term survival of using multiple arterial grafting vs. single arterial grafting in women and men undergoing coronary artery bypass grafting.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The retrospective study used the Australian and New Zealand Society of Cardiothoracic Surgical Database with linkage to the National Death Index. Patients from 2001 to 2020 were identified. Sex-stratified, inverse probability weighted Cox proportional hazard model was used to facilitate survival comparisons. The primary outcome was all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total number of 54 275 adult patients receiving at least two grafts in primary isolated bypass operations were analysed. The entire study cohort consisted of 10 693 (19.7%) female patients and 29 711 (54.7%) multiple arterial grafting procedures. At a median (interquartile range) postoperative follow-up of 4.9 (2.3-8.4) years, mortality was significantly lower in male patients undergoing multiarterial than single arterial procedures (adjusted hazard ratio 0.82; 95% confidence interval 0.77-0.87; P &lt; .001). The survival benefit was also significant for females (adjusted hazard ratio 0.83; 95% confidence interval 0.76-0.91; P &lt; .001) at a median (interquartile range) follow-up of 5.2 (2.4-8.7) years. The interaction model from Cox regression suggested insignificant subgroup effect from sex (P = .08) on the observed survival advantage. The survival benefits associated with multiple arterial grafting were consistent across all sex-stratified subgroups except for female patients with left main coronary disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared to single arterial grafting, multiple arterial revascularization is associated with improved long-term survival for women as well as men.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38820177/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38820177</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae294>10.1093/eurheartj/ehae294</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38820177</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Justin Ren</dc:creator>
<dc:creator>Andrea Bowyer</dc:creator>
<dc:creator>David H Tian</dc:creator>
<dc:creator>Colin Royse</dc:creator>
<dc:creator>Doa El-Ansary</dc:creator>
<dc:creator>Alistair Royse</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multiple arterial vs. single arterial coronary artery bypass grafting: sex-related differences in outcomes</dc:title>
<dc:identifier>pmid:38820177</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae294</dc:identifier>
</item>
<item>
<title>Expression of Concern: Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38820075/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240603222604&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae282. doi: 10.1093/eurheartj/ehae282. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38820075/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240603222604&v=2.18.0.post9+e462414">38820075</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae282>10.1093/eurheartj/ehae282</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38820075</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Expression of Concern: Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk</dc:title>
<dc:identifier>pmid:38820075</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae282</dc:identifier>
</item>





























</channel>
</rss>